Matrix metalloproteinase-2 and -9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Feng, Saran ^a,c   Cen, Jiannong ^a   Huang, Yihong ^b   Shen, Hongjie ^a   Yao, Li ^a   Wang, Yuanyuan ^a   Chen, Zixing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

^c XUZHOU CENTRAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 5; GELATIN; GELATINASE A; GELATINASE B; ILOMASTAT; OCCLUDIN; PROTEIN ZO1; CLAUDIN; CLDN5 PROTEIN, HUMAN; DIPEPTIDE; MEMBRANE PROTEIN; PHOSPHOPROTEIN; PROTEINASE INHIBITOR; ZONULA OCCLUDENS-1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CANCER INVASION; CARCINOMA IN SITU; CENTRAL NERVOUS SYSTEM LEUKEMIA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; RNA INTERFERENCE; UPREGULATION; ZYMOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; BRAIN; CELL STRAIN HL 60; CELL STRAIN U937; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOBLOTTING; LEUKEMIA; METABOLISM; PATHOLOGY; PERMEABILITY; TIGHT JUNCTION; TUMOR CELL LINE;

MUS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE, TUMOR; CLAUDINS; DIPEPTIDES; FLUORESCENT ANTIBODY TECHNIQUE; HL-60 CELLS; HUMANS; IMMUNOBLOTTING; LEUKEMIA; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; PERMEABILITY; PHOSPHOPROTEINS; PROTEASE INHIBITORS; RNA INTERFERENCE; TIGHT JUNCTIONS; U937 CELLS;

EID: 80051709700     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020599     Document Type: Article

References (46)

1. Laningham FH, Kun LE, Reddick WE, Ogg RJ, Morris EB, et al. (2007) Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. Neuroradiology 49: 873-8.
2. Pui CH, Howard SC, (2008) Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 9: 257-68.
3. Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG, (2005) Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol 23: 9172-8.
4. Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, et al. (2006) Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer 106: 2540-6.
5. Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, et al. (2008) Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 22: 2142-50.
6. Rascher G, Fischmann A, Kröger S, Duffner F, Grote EH, et al. (2002) Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol 104: 85-91.
7. Romero IA, Radewicz K, Jubin E, Michel CC, Greenwood J, et al. (2003) Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells. Neurosci Lett 344: 112-6.
8. Zlokovic BV, (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: 178-201.
9. Martin TA, Mansel RE, Jiang WG, (2002) Antagonistic effect of NK4 on HGF/SF induced changes in the transendothelial resistance (TER) and paracellular permeability of human vascular endothelial cells. J Cell Physiol 192: 268-75.
10. Liebner S, Kniesel U, Kalbacher H, Wolburg H, (2000) Correlation of tight junction morphology with the expression of tight junction proteins in blood-brain barrier endothelial cells. Eur J Cell Biol 79: 707-17.
11. Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM, (1998) The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem 273: 29745-53.
12. Latorre IJ, Roh MH, Frese KK, Weiss RS, Margolis B, et al. (2005) Viral oncoprotein-induced mislocalization of select PDZ proteins disrupts tight junctions and causes polarity defects in epithelial cells. J Cell Sci 118: 4283-93.
13. Fedwick JP, Lapointe TK, Meddings JB, Sherman PM, Buret AG, (2005) Helicobacter pylori activates myosin light-chain kinase to disrupt claudin-4 and claudin-5 and increase epithelial permeability. Infect Immun 73: 7844-52.
14. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES, (2004) The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 50: 87-100.
15. Janowska-Wieczorek A, Marquez LA, Matsuzaki A, Hashmi HR, Larratt LM, et al. (1999) Expression of matrix metalloproteinases (MMP-2 and-9) and tissue inhibitors of metalloproteinases (TIMP-1 and-2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J Haematol 105: 402-11.
16. Lin LI, Lin DT, Chang CJ, Lee CY, Tang JL, et al. (2002) Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol 117: 835-41.
17. Suminoe A, Matsuzaki A, Hattori H, Koga Y, Ishii E, (2007) Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement. Leuk Res 31: 1437-40.
18. Asahi M, Wang X, Mori T, Sumii T, Jung JC, et al. (2001) Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21: 7724-32.
19. Cunnea P, McMahon J, O'Connell E, Mashayekhi K, Fitzgerald U, et al. (2010) Gene expression analysis of the microvascular compartment in multiple sclerosis using laser microdissected blood vessels. Acta Neuropathol 119: 601-15.
20. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA, (2007) Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 27: 697-709.
21. Bauer AT, Bürgers HF, Rabie T, Marti HH, (2010) Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J Cereb Blood Flow Metab 30: 837-48.
22. Chen S, Xue Y, Zhang X, Wu Y, Pan J, et al. (2005) A new human acute monocytic leukemia cell line SHI-1 with t(6;11)(q27;q23), p53 gene alterations and high tumorigenicity in nude mice. Haematologica 90: 766-75.
23. Ries C, Egea V, Karow M, Kolb H, Jochum M, et al. (2007) MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 109: 4055-63.
24. Wang C, Chen Z, Li Z, Cen J, (2010) The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells. Leuk Res 34: 1083-90.
25. Oku N, Sasabe E, Ueta E, Yamamoto T, Osaki T, (2006) Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res 66: 5251-7.
26. Li Z, Chen Z, Lu J, Cen J, He J, et al. (2006) Establishment of a nude mice model of human monocytic leukemia with CNS and multiorgan extramedullary infiltration. Eur J Haematol 77: 128-33.
27. Suminoe A, Matsuzaki A, Hattori H, Koga Y, Ishii E, et al. (2007) Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement. Leuk Res 31: 1437-40.
28. Martin TA, Jiang WG, (2009) Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta 1788: 872-91.
29. Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, (2010) Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur J Haematol 84: 239-51.
30. Paupert J, Mansat-De Mas V, Demur C, Salles B, Muller C, (2008) Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle 7: 1047-53.
31. Liu W, Hendren J, Qin XJ, Shen J, Liu KJ, (2009) Normobaric hyperoxia attenuates early blood-brain barrier disruption by inhibiting MMP-9-mediated occludin degradation in focal cerebral ischemia. J Neurochem 108: 811-20.
32. Wang W, Dentler WL, Borchardt RT, (2001) VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol 280: H434-40.
33. Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR, (2009) VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci U S A 106: 1977-82.
34. Wolburg H, Lippoldt A, (2002) Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 38: 323-37.
35. Seelbach M, Chen L, Powell A, Choi YJ, Zhang B, et al. (2010) Polychlorinated biphenyls disrupt blood-brain barrier integrity and promote brain metastasis formation. Environ Health Perspect 118: 479-84.
36. Martin TA, Jiang WG, (2001) Tight junctions and their role in cancer metastasis. Histol Histopathol 16 (4): 1183-95.
37. Chen KM, Liu JY, Lai SC, Hsu LS, Lee HH, (2006) Association of plasminogen activators and matrix metalloproteinase-9 proteolytic cascade with blood-CNS barrier damage of angiostrongyliasis. Int J Exp Pathol 87: 113-9.
38. Demers M, Couillard J, Bélanger S, St-Pierre Y, (2005) New roles for matrix metalloproteinases in metastasis. Crit Rev Immunol 25: 493-523.
39. Deryugina EI, Quigley JP, (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34.
40. Egeblad M, Werb Z, (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-74.
41. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA, (2007) Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 27: 697-709.
42. Rosenberg GA, Yang Y, (2007) Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus 22: E4.
43. Tsukita S, Furuse M, (1999) Occludin and claudins in tight-junction strands: leading or supporting players? Trends Cell Biol 9: 268-73.
44. Balda MS, Matter K, (2008) Tight junctions at a glance. J Cell Sci 121: 3677-82.
45. Fujimoto M, Takagi Y, Aoki T, Hayase M, Marumo T, et al. (2008) Tissue inhibitor of metalloproteinases protect blood-brain barrier disruption in focal cerebral ischemia. J Cereb Blood Flow Metab 28: 1674-85.
46. Lischper M, Beuck S, Thanabalasundaram G, Pieper C, Galla HJ, (2010) Metalloproteinase mediated occludin cleavage in the cerebral microcapillary endothelium under pathological conditions. Brain Res 1326: 114-27.